<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">ETIDRONATE DISODIUM <img border="0" src="../images/pr.gif"/></span><br/>(e-ti-droe'nate)<br/><span class="topboxtradename">Didronel, </span><span class="topboxtradename">Didronel IV, </span><span class="topboxtradename">EHDP<br/></span><b>Classifications:</b> <span class="classification">bisphosphonate</span>; <span class="classification">regulator, bone metabolism</span><br/><b>Pregnancy Category: </b>B (PO); C (parenteral)<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>200 mg, 400 mg tablets; 300 mg ampule</p>
<h1><a name="action">Actions</a></h1>
<p>Diphosphate preparation with primary action on bone. Reduces elevated cardiac output associated with Paget's disease by decreasing
         vascularity of bone. Induces reversible hyperphosphatemia without adverse effects.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Slows rate of bone resorption and new bone formation in pagetic bone lesions and in normal remodeling process. Lowers serum
         alkaline phosphatase. Response of Paget's disease may be slow (13 mo) and may continue for months after treatment is
         discontinued.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Symptomatic Paget's disease and heterotopic ossification due to spinal cord injury or after total hip replacement.</p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>To prevent parathyroid hormone-induced bone resorption, management of malignancy-associated hypercalcemia, treatment of osteoporosis.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Enterocolitis; children; pathologic fractures; pregnancy (category B, oral; category C, parenteral). Safety during lactation
         or in children is not established.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Renal impairment; patients on restricted calcium and vitamin D intake.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Paget's Disease</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 510 mg/kg/d for up to 6 mo or 1120 mg/kg/d for up to 3 mo, may repeat after 36 mo off the drug if necessary<br/><br/><span class="indicationtitle">Heterotopic Ossification Due to Spinal Cord Injury</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 20 mg/kg/d for 2 wk, then 10 mg/kg/d for an additional 10 wk<br/><br/><span class="indicationtitle">Heterotopic Ossification Due to Total Hip Arthroplasty</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 20 mg/kg/d starting 1 mo before the procedure and continuing for 3 mo after<br/><br/><span class="indicationtitle">Malignancy-Associated Hypercalcemia</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 7.5 mg/kg/d for 37 d diluted in at least 250 mL NS and infused over at least 2 h, may repeat after 7 d off the drug
               if necessary<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give as single dose on empty stomach 2 h before meals with full glass of water or juice to reduce gastric irritation.</li>
<li>Relieve GI adverse effects by dividing total oral daily dose.</li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype"> IV Infusion:</span>  Dilute a single dose in at least 250 mL of NS.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">IV Infusion:</span> Give IV slowly over a period of at least 2 h.  
               </p>
</td>
</tr>
</table>
<ul>
<li>Store all forms at 15°30° C (59°86° F) in tightly closed container unless otherwise directed.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">GI:</span> Nausea, diarrhea, <span class="speceff-common">loose bowel movements,</span> metallic or altered taste. <span class="typehead">Musculoskeletal:</span> Increased or recurrent bone pain in pagetic sites, onset of bone pain in previously asymptomatic sites, increased risk of
      fractures in patient with Paget's disease. <span class="typehead">Metabolic:</span> Hypocalcemia, hyperphosphatemia, elevated serum phosphatase, suppressed mineralization of uninvolved skeleton (focal osteomalacia). <span class="typehead">Urogenital:</span> Renal insufficiency (high IV doses). 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> <span class="classification">calcium supplements</span>, <span class="classification">antacids</span>, <span class="classification">iron and other mineral supplements</span> may decrease absorption of etidronate (give etidronate 2 h before other drugs). <span class="typehead">Food:</span> Food, especially milk and dairy products, will decrease absorption of etidronate (give 2 h before meals). 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Variably absorbed from GI tract. <span class="typehead">Distribution:</span> 50% of absorbed drug is distributed to bone. <span class="typehead">Metabolism:</span> Not metabolized. <span class="typehead">Elimination:</span> 50% of absorbed dose is excreted in urine. <span class="typehead">Half-Life:</span> 6 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Report persistent nausea or diarrhea; GI adverse effects may interfere with adequate nutritional status and need to be treated
            promptly.
         </li>
<li>Monitor I&amp;O ratio, serum creatinine, or BUN of patient with impaired kidney function.</li>
<li>Lab tests: Periodic serum calcium and phosphate.</li>
<li>Monitor for signs of hypocalcemia. Latent tetany (hypocalcemia) may be detected by Chvostek's and Trousseau's signs and a
            serum calcium value of 78 mg/dL.
         </li>
<li> 							Note: Serum phosphate levels generally return to normal 24 wk after medication is discontinued. 						</li>
<li>Note: Patients may experience a metallic taste during IV administration.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Avoid eating 2 h before or after taking PO etidronate. Drug absorption is decreased by food, especially milk, milk products,
            and other foods high in calcium, mineral supplements, and antacids.
         </li>
<li>Notify physician promptly of sudden onset of unexplained pain. Risk of pathological fractures increases when daily dose of
            20 mg/kg is taken longer than 3 mo.
         </li>
<li>Report promptly if bone pain, restricted mobility, heat over involved bone site occur.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>